A growing number of Americans are trying popular weight-loss drugs touted by celebrities, health care providers and others.

Hims & Hers Health continues to eye personalized services and global expansion. Read more on what investors should know about ...

These popular medications are now at the center of a major weight loss drug lawsuit. Find out which drugs and involved and ...

With the recent approval in China of Innovent Biologics' (OTCPK:IVBIY) mazdutide as the first-ever dual GLP-1/glucagon ...

A fast-growing group of Americans are turning to what many call the "gray market" for obesity medicines, bringing cheap ...

Taking to platforms including Reddit and Telegram for guidance, buyers import small quantities, often described as research ...

Under the deal, cash-paying patients can access a month’s supply of Wegovy through the Danish drugmaker’s Novocare pharmacy for $299. The one-time price will also be available through Novo’s other ...

Though much of the dust has settled around Novo Nordisk and Eli Lilly’s crusade against compounded GLP-1s, the recent ...

In the race to make the most tolerable obesity drug, there seems to be no clear winner—at least not according to analysts ...

GLP-1 agonists like Wegovy, Ozempic, and Mounjaro might benefit heart and brain health—but research suggests they might also ...

The stock's market-beating momentum has come crashing to a halt, following shocking allegations from one of the world's largest pharmaceutical companies.

A separate Prime analysis, however, of year-over-year claims data for Wegovy and Zepbound only found an improvement in ...